Form 4: Alto Neuroscience Director Husseini Manji Acquires Stock Options

Director Husseini Manji acquired stock options in Alto Neuroscience, Inc. on May 13, 2025, according to a Form 4 filing.

Summary

• Husseini Manji, a director of Alto Neuroscience, Inc., acquired 15,287 stock options on May 13, 2025.
• The options have an exercise price of $2.37.
• The options vest on the earlier of the one-year anniversary of the grant date or the date of the Issuer's next Annual Meeting following the date of grant, subject to continuous service.
• The options expire on May 12, 2035.
• The grant was made pursuant to the Issuer's Non-Employee Director Compensation Policy.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to director compensation. The acquisition of options is generally a positive signal, but it's not a major event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders who have transactions in their company's stock. It reflects standard compensation practices for non-employee directors.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors in publicly traded companies, aligning their interests with those of shareholders.
• The vesting schedule and exercise price are typical for such grants.

Key Dates

Keywords

stock options, Form 4, director, acquisition, Alto Neuroscience, ANRO, Manji Husseini